Q-omics provides the consensus-scored CES4A profile across patient tissues and cancer cell-line models. CES4A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CES4A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CES4A RNA expression shows 17,966 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where CES4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CES4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CES4A survival associations across molecular data types. CES4A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CES4A RNA expression–survival associations across cancer types. High CES4A expression shows unfavorable associations in KIRP, MESO and LAML, but favorable associations in ACC, LUAD and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for CES4A RNA expression.
This table summarizes CES4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CES4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CES4A shows lower tumor expression in KICH, LUSC, LIHC and UCEC and higher tumor expression in KIRC and COAD. The KIRC box plot shows higher CES4A RNA expression in tumor versus normal tissue (log2 FC = +2.602, t-test p < 0.001).
This table shows molecular features associated with CES4A in patient tissues and cancer cell lines. In patient samples, CES4A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CES4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
